Clinical trials: Skin to Skin
Rheumatoid Arthritis
GLPG0259 in Methotrexate-refractory Rheumatoid Arthritis
Part A: 30 patients suffering from active rheumatoid arthritis despite continued treatment with methotrexate will receive once daily two capsules containing either GLPG0259 (25 mg/capsule) or matching placebo, for 12 weeks.
- Trial name
- NCT01211249
- Testing
- GLPG0259 oral capsule, GLPG0259 (Part B)
- Where
- 32 sites in Belgium, Netherlands and 3 more
- Volunteers
- 30 people
- Sponsor
- Lakefront Biotherapeutics NV
Venous Leg Ulcer (VLU)
ConvaVAC™ Ag+ Negative Pressure Wound Therapy System in Chronic Wounds
Purpose of this study is to learn more about how safe and effective the ConvaVAC™ Ag+ wound therapy system is in treating certain types of long-lasting wounds, called chronic wounds.
- Trial name
- ConvaVAC VLU (NCT07342049)
- Testing
- ConvaVAC™ Ag+ Negative Pressure Wound Therapy System
- Where
- 7 sites in Chile, United Kingdom
- Volunteers
- 87 people
- Sponsor
- ConvaTec Inc.
Mucopolysaccharidosis II
A Study of Tividenofusp Alfa (DNL310) in Pediatric Participants With Hunter Syndrome
This is a multicenter, multiregional, open-label study to assess the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of tividenofusp alfa (DNL310), an investigational central nervous system (CNS)-penetrant enzyme…
- Trial name
- NCT04251026
- Testing
- tividenofusp alfa
- Where
- 7 sites in United States, Canada and 2 more
- Volunteers
- 47 people
- Sponsor
- Denali Therapeutics Inc.
Breast Cancer
Tumour Registry Breast Cancer
The registry aims to collect and analyse information on the antineoplastic treatment of breast cancer in daily routine practice of office-based and clinic-based medical oncologists in Germany.
- Trial name
- TMK (NCT01351584)
- Volunteers
- 4,500 people
- Sponsor
- iOMEDICO AG
Rheumatoid Arthritis
Long-term Treatment Study of MRA for Rheumatoid Arthritis (RA) From Study MRA012JP
This is an open-label, extension, Phase III study to evaluate the long-term safety and efficacy of MRA in patients with RA who participated in Study MRA012JP.
- Trial name
- NCT00144547
- Testing
- MRA(Tocilizumab)
- Volunteers
- 241 people
- Sponsor
- Chugai Pharmaceutical
Rheumatoid Arthritis
Study to Assess the Safety and Efficacy of Etanercept in Patients Treated Over the Long-term in Real-world Clinical Practice, Using Data Collected by the British Society of Rheumatology Biologics Registry
This study will assess the rates of serious adverse events and death in adult rheumatoid arthritis patients treated with etanercept over the long-term in real-life clinical practice.
- Trial name
- NCT01646385
- Testing
- etanercept, non-biologic anti-rheumatic drugs
- Volunteers
- 6,393 people
- Sponsor
- Pfizer
Atopic Dermatitis
Tralokinumab Monotherapy for Moderate to Severe Atopic Dermatitis - ECZTRA 2 (ECZema TRAlokinumab Trial no. 2)
Primary objective: To evaluate the efficacy of tralokinumab compared with placebo in treating moderate to severe atopic dermatitis (AD).
- Trial name
- ECZTRA 2 (NCT03160885)
- Testing
- Tralokinumab
- Where
- 115 sites in United States, Australia and 7 more
- Volunteers
- 794 people
- Sponsor
- LEO Pharma
Keloid
Efficacy, Safety, and Tolerability of Remlarsen (MRG-201) Following Intradermal Injection in Subjects With a History of Keloids
Remlarsen (MRG-201) is designed to mimic the activity of a molecule called miR-29 that decreases the expression of collagen and other proteins that are involved in scar formation.
- Trial name
- NCT03601052
- Testing
- Remlarsen
- Where
- 4 sites in United States
- Volunteers
- 14 people
- Sponsor
- miRagen Therapeutics, Inc.
Actively Extending Plaque Psoriasis, Moderate to Severe Plaque Psoriasis
Trial of IMO-3100 in Patients With Moderate to Severe Plaque Psoriasis
The purpose of this study is to evaluate different dose levels of IMO-3100 compared to placebo administered for 4 weeks to patients with moderate to severe plaque psoriasis.
- Trial name
- NCT01622348
- Testing
- IMO-3100 at 0.16 mg/kg, Saline for Injection, IMO-3100 at 0.32 mg/kg
- Where
- 13 sites in United States
- Volunteers
- 44 people
- Sponsor
- Idera Pharmaceuticals, Inc.
Alopecia, Androgenetic
A Study of TDM-105795 in Male Subjects With Androgenetic Alopecia (AGA)
Multi-center, randomized, double-blind, vehicle-controlled, parallel group, multi-dose escalation study of TDM-105795 in male subjects, 18 to 55 years old, with Androgenetic Alopecia (AGA).
- Trial name
- NCT05244980
- Testing
- TDM-105795
- Where
- 2 sites in United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Technoderma Medicines Inc.
Breast Cancer
Trastuzumab Plus Paclitaxel in Treating Women With Metastatic Breast Cancer That Overexpresses HER2
RATIONALE: Monoclonal antibodies, such as trastuzumab, can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00005635
- Testing
- trastuzumab, paclitaxel
- Where
- United States
- Sponsor
- Genentech, Inc.
Hypochondroplasia
An Interventional Study of Infigratinib in Children With Hypochondroplasia
ACCEL2/3 is a Phase 2/3 study. The purpose of the Phase 2 portion of the study (ACCEL2/3) is to evaluate the efficacy and safety of infigratinib in children with hypochondroplasia (HCH) receiving infigratinib at one of two doses…
- Trial name
- HCH (NCT06873035)
- Testing
- infigratinib 0.128 mg/kg/day, infigratinib 0.25 mg/kg/day
- Where
- 24 sites in United States, Australia and 8 more
- Volunteers
- 24 people
- Sponsor
- QED Therapeutics, a BridgeBio company
Metastatic Breast Cancer
Demonstrate Efficacy and Safety of Metastatic Breast Cancer
The purpose of the study is to demonstrate equivalence
- Trial name
- Compare (NCT01084876)
- Testing
- CT-P6, Herceptin, Paclitaxel
- Where
- South Korea
- Volunteers
- 475 people
- Sponsor
- Celltrion
Rheumatoid Arthritis
Moderate Rheumatoid Arthritis (RA) With Etanercept (Enbrel)
This study is designed to evaluate the effectiveness of adding etanercept to disease modifying anti-rheumatic drug (DMARD) therapy in patients with moderately active Rheumatoid Arthritis (RA).
- Trial name
- NCT01313208
- Testing
- etanercept, DMARD Therapy
- Where
- 47 sites in United States, Canada
- Volunteers
- 210 people
- Sponsor
- Amgen
Basal Cell Carcinoma
Reflectance Confocal Microscopy to Diagnose BCC
It is proposed to undertake a study to determine the diagnostic utility of using RCM for the diagnosis of Basal Cell Carcinoma (BCC) in a tertiary referral centre as outlined by the recent NICE report (Nov 2015).
- Trial name
- NCT03509415
- Testing
- In-vivo imaging
- Where
- United Kingdom
- Volunteers
- 324 people
- Sponsor
- Skin Care Network Ltd.
Atopic Dermatitis
A Study of KT-621 Administered Orally to Participants With Moderate to Severe Atopic Dermatitis
This phase 2b study is designed to evaluate the safety and efficacy of KT-621 in adult and adolescent participants with moderate-to-severe atopic dermatitis (AD), a common form of eczema.
- Trial name
- BROADEN2 (NCT07217015)
- Testing
- KT-621
- Where
- 61 sites in United States, Australia and 6 more
- Volunteers
- 200 people
- Sponsor
- Kymera Therapeutics, Inc.
Psoriatic Arthritis
Efficacy and Safety of HS-10374 Compared to Placebo in Adults With Active Psoriatic Arthritis
This study has been designed to explore the clinical efficacy and safety of HS-10374 in the treatment of active psoriatic arthritis.
- Trial name
- NCT06176508
- Testing
- HS-10374, Tofacitinib 5Mg Tab,Oral
- Where
- China
- Volunteers
- 160 people
- Sponsor
- Hansoh BioMedical R&D Company
Acne Vulgaris
Photodynamic Therapy (PDT) With Methyl Aminolevulinate (MAL) Cream in Moderate to Severe Acne
This multicenter study will be divided into 2 phases. The first phase will be an open label, dose-escalation phase, while the second will be a blinded, randomized, vehicle-controlled, parallel-group, dose-response phase.
- Trial name
- NCT00594425
- Testing
- Methyl aminolevulinate (MAL) PDT
- Where
- 14 sites in United States
- Volunteers
- 150 people
- Sponsor
- Photocure
Dermatitis, Allergic Contact, Infectious Diseases
Incidence of Allergic Manifestations and Infectious Episodes in Healthy Term Infants at Risk for Dysbiosis
This study will evaluate the incidence of allergic manifestations (the first of which is atopic dermatitis) and infectious diseases in children fed with an infant formula under real conditions of use.
- Trial name
- SOPRANO (NCT04182425)
- Testing
- Infant formula
- Where
- France
- Volunteers
- 334 people, healthy volunteers welcome
- Sponsor
- Bledina
Systemic Lupus Erythematosus
A Study of AMG 557 in Adults With Systemic Lupus Erythematosus
This is a Phase 1, randomized, placebo-controlled, double-blind, dose-escalation study of repeat SC doses of AMG 557 in adults with Systemic Lupus Erythematosus.
- Trial name
- NCT00774943
- Testing
- AMG 557
- Where
- 12 sites in United States, Canada
- Volunteers
- 58 people
- Sponsor
- Amgen
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.